AssetMark Inc
MRNA icon

AssetMark Inc’s Moderna MRNA Stock Holding History

AssetMark Inc’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$176K Buy
912
+114
+14% +$12.3K ﹤0.01% 1505
2026
Q2 		$55.9K Sell
798
-3
-0.4% -$155 ﹤0.01% 1799
2026
Q1 		$40.7K Buy
801
+208
+35% +$9.7K ﹤0.01% 1819
2025
Q4 		$17.5K Sell
593
-531
-47% -$14.4K ﹤0.01% 2041
2025
Q3 		$29K Sell
1,124
-174
-13% -$4.85K ﹤0.01% 1819
2025
Q2 		$35.8K Buy
1,298
+752
+138% +$19.8K ﹤0.01% 1656
2025
Q1 		$15.5K Buy
546
+179
+49% +$6.35K ﹤0.01% 1757
2024
Q4 		$15.2K Buy
367
+136
+59% +$6.5K ﹤0.01% 1712
2024
Q3 		$15.4K Sell
231
-45,938
-99% -$4.22M ﹤0.01% 1552
2024
Q2 		$5.48M Sell
46,169
-3,469
-7% -$439K 0.02% 416
2024
Q1 		$5.29M Sell
49,638
-569,514
-92% -$57.4M 0.02% 402
2023
Q4 		$61.6M Buy
619,152
+403,428
+187% +$33.9M 0.22% 97
2023
Q3 		$22.3M Buy
215,724
+47,667
+28% +$5.32M 0.09% 178
2023
Q2 		$20.4M Sell
168,057
-309,310
-65% -$41.3M 0.08% 189
2023
Q1 		$73.3M Buy
477,367
+262,782
+122% +$43.4M 0.3% 70
2022
Q4 		$38.5M Sell
214,585
-15,251
-7% -$2.49M 0.17% 130
2022
Q3 		$27.2M Buy
229,836
+2,193
+1% +$333K 0.13% 142
2022
Q2 		$32.5M Buy
227,643
+2,285
+1% +$327K 0.15% 137
2022
Q1 		$38.8M Buy
225,358
+186,660
+482% +$31.4M 0.16% 131
2021
Q4 		$9.8M Buy
38,698
+38,450
+15,504% +$11.2M 0.04% 222
2021
Q3 		$95K Buy
248
+238
+2,380% +$87.8K ﹤0.01% 654
2021
Q2 		$2K Buy
+10
New +$1.79K ﹤0.01% 1208

Other funds holding MRNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures
Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Lingotto Investment Management
Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

AssetMark Inc's MRNA Position: Q3 2026 in Review

AssetMark Inc increased its Moderna (MRNA) stake by 14% in Q3 2026, buying an estimated $12.3K and bringing the position to 912 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

AssetMark Inc first reported a position in MRNA in Q2 2021 and has held it in 22 quarters since. The position peaked at $73.3M in Q1 2023. 530 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • AssetMark Inc held 912 shares of Moderna worth $176K as of Q3 2026.
  • AssetMark Inc bought 114 Moderna shares in Q3 2026, an estimated $12.3K.
  • Moderna made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #1505 holding.
  • AssetMark Inc first reported a position in Moderna in Q2 2021 and has held it in 22 quarters since.
  • AssetMark Inc's Moderna position peaked at $73.3M in Q1 2023.
  • 530 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.